samedan logo
 
 
spacer
home > pmps > summer 2002 > developing custom adhesive systems for transdermal drug delivery products
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Developing Custom Adhesive Systems for Transdermal Drug Delivery Products

Pharmaceutical companies in search of unique pressure-sensitive adhesive systems for their transdermal drug delivery (TDD) products are turning to specialty adhesives manufacturers to carry out research and development, testing, materials qualification, manufacturing, quality and other product development tasks. Trends suggest that adhesives manufacturers are forming partnerships with pharmaceutical companies as part of the product development process that ultimately includes manufacturing adhesive products to the relevant pharmaceutical current Good Manufacturing Practices (cGMPs). This article also discusses the technological advances that are occurring in terms of types of transdermal patch, adhesive properties and specialised components in transdermal drug delivery systems (TDDS).

Transdermal Drug Delivery Systems

The use of TDDS continues to gain market acceptance as a selected method of drug administration. The success of products that deliver materials such as nicotine for smoking cessation, nitroglycerin for angina, oestradiol and testosterone for hormone replacement therapy, and oestrogen and progesterone for birth control has ensured that the TDDS market is a strong industry segment with many more drug actives being formulated for transdermal delivery methods.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Melinda Hopp, Director of Marketing at Adhesives Research, Inc. Melinda Hopp has served as Director of Marketing at Adhesives Research, Inc. for the past six years. She previously worked for Southern New England Telephone as Director of Business Development; Duracell, Inc. (a division of Gillette Company) as Director of Market Development; and Novo Laboratories USA (a former division of NovoNordisk, Denmark) as Director of Market Research.
She started her career as a Research Chemist with Lehn & Fink Products (then a division of Sterling Drug). She has a BA in Biology/Chemistry, an MA in Science and an MBA from Fairleigh Dickinson University in New Jersey, US.

spacer
Melinda Hopp
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Global pharma industry gathers at CPhI Worldwide 2021 as surge in partnering expected in 2022

Over 25,000 online and 23,000 in person attendees at the world’s largest pharma trade exhibition. CPhI Worldwide (9-11 November, 2021), which held its first in-person event since 2019, hosted the global pharma community at the Fiera Milano, Milan, welcoming exhibitors and attendees from 146 countries.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement